Brief: Botanix Pharmaceuticals Says Completed Resubmission Of New Drug Application For Sofdra
20/12/2023 23:21
Dec 21 (Reuters) - Botanix Pharmaceuticals Ltd BOT.AX :
* SUCCESSFULLY COMPLETED RESUBMISSION OF NEW DRUG
APPLICATION FOR
SOFDRA
* COMMERCIAL PREPARATIONS FOR LAUNCH OF SOFDRA ARE UNDERWAY
AS
TARGET FOR FDA APPROVAL HAS NOW BEEN MOVED UP TO LATE 2Q 2024
Source text for Eikon: ID:nASX76M4DM
Further company coverage: BOT.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Botanix Pharmaceuticals
See all newsBrief: Botanix Pharmaceuticals Receives Notice Of Allowance For Additional US Patent Covering Sofdra Drug Substance
Brief: Botanix Pharmaceuticals Appoints Paul Seaback As Chief Operating Officer
Brief: Botanix Pharmaceuticals Reaches Term Sheet Agreement With Second API Supplier
Botanix Pharmaceuticals jumps on supply agreement with PPL Pharma Solutions
Brief: Botanix Pharmaceuticals Posts HY Loss Attributable A$33.2 Million